Characterisation of human surfactant protein A and recombinant human vimentin in their modulation of HPV16 pseudovirus infection
| dc.contributor.advisor | Schafer, Georgia | |
| dc.contributor.advisor | Katz, Arieh | |
| dc.contributor.author | Carse, Sinead | |
| dc.date.accessioned | 2020-04-30T07:39:24Z | |
| dc.date.available | 2020-04-30T07:39:24Z | |
| dc.date.issued | 2019 | |
| dc.date.updated | 2020-04-30T07:02:52Z | |
| dc.description.abstract | Infection by oncogenic human papillomavirus (HPV) is the primary cause of cervical cancer, where low-and middle-income countries (LMIC) have the highest incidence. Prophylactic HPV vaccines exist but LMIC have limited access. Therefore, alternative preventative measures against HPV infection and cervical cancer progression are needed. Two human proteins have been identified in our laboratory that modulate HPV16 pseudovirus (HPV16-PsVs) infection in vitro, namely surfactant protein A (SP-A) and recombinant human vimentin (rhVim). Previous work suggested SP-A mediated immune recognition of HPV since SP-A-coated HPV16- PsVs enhanced viral uptake by RAW264.7 murine macrophages. These initial observations were confirmed using a murine C57BL/6 cervicovaginal challenge model: pre-incubation of HPV16- PsVs with purified human SP-A significantly reduced the level of HPV16-PsV infection in vivo. Moreover, when isolated cells from female reproductive tracts of naïve C57BL/6 mice were incubated with HPV16-PsVs and stained for selected innate immune cell populations by flow cytometry, significant increases in viral uptake by eosinophils, neutrophils, monocytes and macrophages were observed over time using SP-A-pre-coated virions compared to control particles. Compared to SP-A mediated modulation of HPV infection through activation of innate immune responses, rhVim was suggested to directly interfere with HPV entry into host cells. Indeed, supplementation with non-filamentous rhVim resulted in decreased viral uptake by NIKS cells which was confirmed in vivo using the murine C57BL/6 cervicovaginal HPV16-PsVs challenge model. Co-localisation analysis employing confocal imaging, revealed that rhVim-coated HPV16- PsVs co-localised, to a lesser degree, with surface-expressed heparan sulphate proteoglycans (HSPGs) than control particles. Removal of surface HSPGs on NIKS cells decreased HPV16-PsVs cell surface binding and internalisation, while pre-incubation of HPV16-PsVs with rhVim decreased viral particle binding and internalisation to a greater extent. This indicates that rhVim may modulate HPV16 infection by interfering with its attachment to HSPGs as well as viral engagement with the yet unknown entry receptor(s). In summary, both SP-A and vimentin modulate HPV16-PsVs infection by different mechanisms. These in vivo studies strongly confirm previous in vitro observations, rendering both proteins potentially suitable for further development into possible candidates for use in topical microbicides, which may provide protection against new HPV infections. | |
| dc.identifier.apacitation | Carse, S. (2019). <i>Characterisation of human surfactant protein A and recombinant human vimentin in their modulation of HPV16 pseudovirus infection</i>. (). ,Faculty of Health Sciences ,Department of Integrative Biomedical Sciences (IBMS). Retrieved from | en_ZA |
| dc.identifier.chicagocitation | Carse, Sinead. <i>"Characterisation of human surfactant protein A and recombinant human vimentin in their modulation of HPV16 pseudovirus infection."</i> ., ,Faculty of Health Sciences ,Department of Integrative Biomedical Sciences (IBMS), 2019. | en_ZA |
| dc.identifier.citation | Carse, S. 2019. Characterisation of human surfactant protein A and recombinant human vimentin in their modulation of HPV16 pseudovirus infection. . ,Faculty of Health Sciences ,Department of Integrative Biomedical Sciences (IBMS). | en_ZA |
| dc.identifier.ris | TY - Thesis / Dissertation AU - Carse, Sinead AB - Infection by oncogenic human papillomavirus (HPV) is the primary cause of cervical cancer, where low-and middle-income countries (LMIC) have the highest incidence. Prophylactic HPV vaccines exist but LMIC have limited access. Therefore, alternative preventative measures against HPV infection and cervical cancer progression are needed. Two human proteins have been identified in our laboratory that modulate HPV16 pseudovirus (HPV16-PsVs) infection in vitro, namely surfactant protein A (SP-A) and recombinant human vimentin (rhVim). Previous work suggested SP-A mediated immune recognition of HPV since SP-A-coated HPV16- PsVs enhanced viral uptake by RAW264.7 murine macrophages. These initial observations were confirmed using a murine C57BL/6 cervicovaginal challenge model: pre-incubation of HPV16- PsVs with purified human SP-A significantly reduced the level of HPV16-PsV infection in vivo. Moreover, when isolated cells from female reproductive tracts of naïve C57BL/6 mice were incubated with HPV16-PsVs and stained for selected innate immune cell populations by flow cytometry, significant increases in viral uptake by eosinophils, neutrophils, monocytes and macrophages were observed over time using SP-A-pre-coated virions compared to control particles. Compared to SP-A mediated modulation of HPV infection through activation of innate immune responses, rhVim was suggested to directly interfere with HPV entry into host cells. Indeed, supplementation with non-filamentous rhVim resulted in decreased viral uptake by NIKS cells which was confirmed in vivo using the murine C57BL/6 cervicovaginal HPV16-PsVs challenge model. Co-localisation analysis employing confocal imaging, revealed that rhVim-coated HPV16- PsVs co-localised, to a lesser degree, with surface-expressed heparan sulphate proteoglycans (HSPGs) than control particles. Removal of surface HSPGs on NIKS cells decreased HPV16-PsVs cell surface binding and internalisation, while pre-incubation of HPV16-PsVs with rhVim decreased viral particle binding and internalisation to a greater extent. This indicates that rhVim may modulate HPV16 infection by interfering with its attachment to HSPGs as well as viral engagement with the yet unknown entry receptor(s). In summary, both SP-A and vimentin modulate HPV16-PsVs infection by different mechanisms. These in vivo studies strongly confirm previous in vitro observations, rendering both proteins potentially suitable for further development into possible candidates for use in topical microbicides, which may provide protection against new HPV infections. DA - 2019 DB - OpenUCT DP - University of Cape Town KW - Medical Biochemistry LK - https://open.uct.ac.za PY - 2019 T1 - Characterisation of human surfactant protein A and recombinant human vimentin in their modulation of HPV16 pseudovirus infection TI - Characterisation of human surfactant protein A and recombinant human vimentin in their modulation of HPV16 pseudovirus infection UR - ER - | en_ZA |
| dc.identifier.uri | https://hdl.handle.net/11427/31719 | |
| dc.identifier.vancouvercitation | Carse S. Characterisation of human surfactant protein A and recombinant human vimentin in their modulation of HPV16 pseudovirus infection. []. ,Faculty of Health Sciences ,Department of Integrative Biomedical Sciences (IBMS), 2019 [cited yyyy month dd]. Available from: | en_ZA |
| dc.language.rfc3066 | eng | |
| dc.publisher.department | Department of Integrative Biomedical Sciences (IBMS) | |
| dc.publisher.faculty | Faculty of Health Sciences | |
| dc.subject | Medical Biochemistry | |
| dc.title | Characterisation of human surfactant protein A and recombinant human vimentin in their modulation of HPV16 pseudovirus infection | |
| dc.type | Master Thesis | |
| dc.type.qualificationlevel | Masters | |
| dc.type.qualificationname | MSc |